Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678329 | 0.83 | CA1 (0.50) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL19806160 | 0.82 | RAPGEF4 (0.46) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL17318144 | 0.79 | CA1 (0.47) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL20310 | 0.79 | F2 (0.50) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL6114533 | 0.77 | CA1 (0.45) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL15000835 | 0.77 | CA1 (0.45) | RAPGEF4CA1CA2MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL28479231 | 0.77 | F2 (0.49) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL330754 | 0.77 | CA1 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL24969530 | 0.76 | CA1 (0.48) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL13114299 | 0.76 | RAPGEF4 (0.47) | RAPGEF4CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12607095-B2 | Dissolution of titanium-iron oxides and iron oxides in a wellbore | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260085230-A1 | DISSOLUTION OF MANGANESE OXIDES IN A WELLBORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-26 | — | — | US | claimed |
| US-20260078654-A1 | DISSOLUTION OF TITANIUM-IRON OXIDES AND IRON OXIDES IN A WELLBORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025264280-A1 | FURFURYL ALCOHOL MONOMER CONSOLIDATION TREATMENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250388801-A1 | FURFURYL ALCOHOL MONOMER CONSOLIDATION TREATMENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-12607095-B2 | Dissolution of titanium-iron oxides and iron oxides in a wellbore | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260085230-A1 | DISSOLUTION OF MANGANESE OXIDES IN A WELLBORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260078654-A1 | DISSOLUTION OF TITANIUM-IRON OXIDES AND IRON OXIDES IN A WELLBORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025264280-A1 | FURFURYL ALCOHOL MONOMER CONSOLIDATION TREATMENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250388801-A1 | FURFURYL ALCOHOL MONOMER CONSOLIDATION TREATMENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3978077-B1 | CONDENSED HETEROCYCLIC COMPOUND HAVING A BRIDGEHEAD NITROGEN ATOM OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE | NIHON NOHYAKU CO LTD (JP) | 2023-11-29 | — | — | EP | disclosed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-8552054-B2 | Anticancer agents, viricides, psychological disorders | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2008090048-A2 | 3-AMINO-1,2-BENZISOTHIAZOLE COMPOUNDS FOR COMBATING ANIMAL PEST II | BASF SE (DE) | 2008-07-31 | — | — | WO | disclosed |
| US-6727294-B2 | RADIATION TRANSPARENT MOLDING MATERIALS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0794218-B1 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20010034419-A1 | Radiation transparent molding materials | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2001-10-25 | — | — | US | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607095-B2 | Dissolution of titanium-iron oxides and iron oxides in a wellbore | TDO2, TRHDE, HAO2 | RAPGEF4 2080/4885CA1 34/4885CA2 49/4885 |
| US-20260085230-A1 | DISSOLUTION OF MANGANESE OXIDES IN A WELLBORE | PWWP2B, WHR1, ADH1A | RAPGEF4 1507/4885CA1 485/4885CA2 2333/4885 |
| US-20250388801-A1 | FURFURYL ALCOHOL MONOMER CONSOLIDATION TREATMENT | CD69, MFAP1, FLOT1 | RAPGEF4 63/4885CA1 857/4885CA2 677/4885 |
| US-20260078654-A1 | DISSOLUTION OF TITANIUM-IRON OXIDES AND IRON OXIDES IN A WELLBORE | TRHDE, TDO2, HAO2 | RAPGEF4 2206/4885CA1 58/4885CA2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.